These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12804101)

  • 1. Thyroid stunning.
    Morris LF; Waxman AD; Braunstein GD
    Thyroid; 2003 Apr; 13(4):333-40. PubMed ID: 12804101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid stunning in clinical practice: is it a real problem?
    Filesi M; Colandrea M; Montesano T; D'Apollo R; Ronga G
    Minerva Endocrinol; 2009 Mar; 34(1):29-36. PubMed ID: 19209126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid stunning: fact or fiction?
    McDougall IR; Iagaru A
    Semin Nucl Med; 2011 Mar; 41(2):105-12. PubMed ID: 21272684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
    Lassmann M; Luster M; Hänscheid H; Reiners C
    J Nucl Med; 2004 Apr; 45(4):619-25. PubMed ID: 15073258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioactive iodine in thyroid medicine--how it started in Sweden and some of today's challenges.
    Mattsson S; Johansson L; Jönsson H; Nosslin B
    Acta Oncol; 2006; 45(8):1031-6. PubMed ID: 17118834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.
    Happel C; Kranert WT; Ackermann H; Binse I; Bockisch B; Gröner D; Herrmann K; Grünwald F
    Endocrine; 2019 Mar; 63(3):537-544. PubMed ID: 30599051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the cell death pathway and apoptosis-stunning effect relationship after low- and high-dose I-131 administrations in rat thyroid tissue.
    Turgut B; Babul A; Ozdemir O; Erselcan T
    Cancer Biother Radiopharm; 2006 Aug; 21(4):342-51. PubMed ID: 16999600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does thyroid stunning exist? A model with benign thyroid disease.
    Sabri O; Zimny M; Schreckenberger M; Meyer-Oelmann A; Reinartz P; Buell U
    Eur J Nucl Med; 2000 Nov; 27(11):1591-7. PubMed ID: 11105814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The so-called stunning of thyroid tissue.
    Sisson JC; Avram AM; Lawson SA; Gauger PG; Doherty GM
    J Nucl Med; 2006 Sep; 47(9):1406-12. PubMed ID: 16954546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans.
    Omür O; Akgün A; Ozcan Z; Sen C; OzkiIiç H
    Clin Nucl Med; 2009 Jan; 34(1):11-4. PubMed ID: 19092374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
    Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C
    J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer.
    Amdur RJ; Dan T; Mazzaferri E
    Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stunning phenomenon after a radioactive iodine- ¹³¹I diagnostic whole-body scan: Is it really a point of clinical consideration?
    Amin A; Amin M; Badwey A
    Nucl Med Commun; 2013 Aug; 34(8):771-6. PubMed ID: 23708870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
    Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
    Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.